They will buy "approximately a fifth" of the energy produced at the 600MW Kriegers Flak project, according to developer Vattenfall.
Novozymes, which produces enzymes for industrial use, sources all power for its production in Denmark from renewable sources.
Its latest clean energy power deal will provide energy across its "whole supply chain, from production to products", vice president for sourcing and facility management, Lene Aabo said.
Meanwhile, Novo Nordisk, which produces insulin, as well as other healthcare products, aims to run all of its production facilities around the world on renewable sources by 2020.
With the Vattenfall agreement, it will have achieved this target at its European plants, head of corporate environmental strategy, Dorethe Nielsen, added.
The Kriegers Flak deal comes into effect on 1 January 2020, but the 72-turbine site is not due to be fully operational until the end of 2021.
Before the project’s full commissioning, Novo Nordisk and Novozymes will source power from "other Vattenfall wind farms in Denmark", the developer added.
Vattenfall has more than 540MW of installed capacity in Denmark across 31 wind farms, according to Windpower Intelligence, the research and data division of Windpower Monthly.
Kriegers Flak will be located in the Baltic Sea, 15 kilometres from the Danish coast. It will comprise 72 of Siemens Gamesa’s SG 8.0-167 DD turbines.
The two cables linking the substations at the Kriegers Flak in Danish waters and EnBW’s 288MW Baltic 2, which is located off the German coast, were installed in July 2018.
It was the first time an interconnector was installed using the infrastructure of offshore wind projects.